Zurück
ocutx.gcs-web.com/static-files/...ebaf-44ed-a6c5-b43099f6fb50
Sehr interessante Pipeline
3 FDA Approvals
Total global market >23B$
Sehr interessante Pipeline
3 FDA Approvals
Total global market >23B$
Top-News
Ocular Therapeutix
Beiträge: 42
Zugriffe: 21.213 / Heute: 5
Zugriffe: 21.213 / Heute: 5
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
SPDR S&P U.S. Technology Select Sector UCITS ETF
Perf. 12M: +43,53%
SPDR MSCI World Technology UCITS ETF
Perf. 12M: +43,05%
SPDR S&P U.S. Communication Serv. Select Sector UCITS ETF Ac
Perf. 12M: +38,15%
SPDR MSCI World Communication Services UCITS ETF
Perf. 12M: +36,94%
SPDR MSCI World Industrials UCITS ETF
Perf. 12M: +30,50%
enttäuschende Phase2 Studienergebnisse von OTX-CSI (in DED)
ocutx.gcs-web.com/news-releases/...e-results-phase-2-clinical
- MK 529 Mio. $
endpts.com/...-a-phii-failure-in-dry-eye-disease-shares-tank/
www.fool.com/investing/2021/10/22/...x-stock-is-sinking-toda/
Zahlen für Q4/ 2021
- Umsatz 12 Mio. $
- oper. Verlust 18 Mio. $
- Cash 164 Mio. $
- MK 336 Mio. $
"the Company believes that existing cash and cash equivalents, as of December 31, 2021, will enable the Company to fund planned operating expenses, debt service obligations and capital expenditure requirements through 2023 "
ocutx.gcs-web.com/news-releases/...-quarter-and-year-end-2021
Zahlen für Q1/22
- Umsatz 13 Mio. $
- oper. Verlust 18 Mio. $
- Cash 145 Mio. $
- MK 250 Mio. $
- Guiding DEXTENZA Annual Net Product Revenue for 2022 between $55 to $60 million
- Topline Data from the U.S.-based Clinical Trial for OTX-TKI for the Treatment of Wet AMD Anticipated in the Third Quarter of 2022
ocutx.gcs-web.com/news-releases/...rst-quarter-2022-financial
Zahlen für Q2/22
- Umsatz 12,3 Mio. $
- Verlust 18,8 Mio. $
- Cash 135 Mio. $
- MK 418 Mio. $
- Interim Data from the U.S.-based Clinical Trial for OTX-TKI for the Treatment of Wet AMD to be Presented at American Academy of Ophthalmology (AAO) in the Third Quarter of 2022
ocutx.gcs-web.com/news-releases/...ond-quarter-2022-financial
Zahlen für Q3/22
- Umsatz 12 Mio. $
- Verlust 24 Mio. $
- Cash 121 Mio. $
- MK 222 Mio. $
ocutx.gcs-web.com/news-releases/...ird-quarter-2022-financial
VORLÄUFIGE 10-MONATSDATEN AUS DER PHASE-1-STUDIE DER USA ZUR BEWERTUNG VON OTX-TKI (wAMD)
ocutx.gcs-web.com/news-releases/...m-10-month-data-ongoing-us
"Ocular Therapeutix: Q1 Earnings Snapshot
05/08/2023 | 05:08pm EDT
BEDFORD, Mass. (AP) — BEDFORD, Mass. (AP) — Ocular Therapeutix Inc. (OCUL) on Monday reported a loss of $30.3 million in its first quarter.
On a per-share basis, the Bedford, Massachusetts-based company said it had a loss of 39 cents. Losses, adjusted for non-recurring costs, came to 31 cents per share.
The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 27 cents per share.
The biotechnology company posted revenue of $13.4 million in the period, which also missed Street forecasts. Four analysts surveyed by Zacks expected $14 million."
www.marketscreener.com/quote/stock/...ings-Snapshot-43781085/
Mal weiter beobachten;
05/08/2023 | 05:08pm EDT
BEDFORD, Mass. (AP) — BEDFORD, Mass. (AP) — Ocular Therapeutix Inc. (OCUL) on Monday reported a loss of $30.3 million in its first quarter.
On a per-share basis, the Bedford, Massachusetts-based company said it had a loss of 39 cents. Losses, adjusted for non-recurring costs, came to 31 cents per share.
The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 27 cents per share.
The biotechnology company posted revenue of $13.4 million in the period, which also missed Street forecasts. Four analysts surveyed by Zacks expected $14 million."
www.marketscreener.com/quote/stock/...ings-Snapshot-43781085/
Mal weiter beobachten;
(Verkleinert auf 31%) 
12-Monats-Topline-Daten aus der Phase-1-Studie in den USA zur Bewertung von OTX-TKI (wAMD)
ocutx.gcs-web.com/news-releases/...th-topline-data-ongoing-us
Zahlen für Q1/23
- Umsatz 13,4 Mio. $
- oper. Verlust 23 Mio. $
- Cash 79 Mio. $
- MK 435 Mio. $
ocutx.gcs-web.com/news-releases/...rst-quarter-2023-financial
OCUL sieht sich bis Mitte 2024 finanziert
Zwar ist die MK auf rund 340 Mio. $ gesunken, aber dennoch sind hier einige Fragen (der Finanzierung) offen. Manche hoffen auf eine Übernahme, andere befürchten ein verwässerendes Offering.
Zahlen für Q2/23
- Umsatz 15 Mio. $
- Verlust 21 Mio. $
- Cash 67 Mio. $
- MK 309 Mio. $
- Closed on a New $82.5 million Credit Facility
investors.ocutx.com/news-releases/...d-quarter-2023-financial
MK 196 Mio. $, die Bewertung ist ein Stück zurückgekommen. Aktuell ist OCUL mit dem 3,3fachen seines Jahresumsatzes bewertet.
Zahlen für Q3/23
- Umsatz 15 Mio. $
- operativer Verlust 19 Mio. $
- Cash 111 Mio. $
- MK 196 Mio. $
- Top-line Data from U.S.-based HELIOS Trial Evaluating AXPAXLI for Treatment of Non-Proliferative Diabetic Retinopathy Anticipated to be Presented in in Q2 2024
- Top-line Data from U.S.-based Phase 2 Clinical Trial of OTX-TIC for Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Anticipated to be Presented at ASCRS Meeting in Early April 2024
investors.ocutx.com/news-releases/...d-quarter-2023-financial
investors.ocutx.com/news-releases/...ubjects-screened-phase-3
Verdreifacht seit November.
Verdreifacht seit November.
|
Neueste Beiträge aus dem Ocular Therapeutix Inc Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 41 | Ocular Therapeutix | NikGol | Vassago | 19.02.24 11:10 |
